$IPHA

Innate Pharma (NASDAQ:IPHA) completed enrollment in the dose-escalation portion of its Phase I trial of IPH4502, enrolling 76 patients by July 21. The company expects 10 to 15 patients at go-forward doses across post-PADCEV urothelial cancer, head and neck cancer, and NSCLC, with dose-escalation data later in 2024. Innate also awaits primary-endpoint data from AstraZeneca’s PACIFIC-9 monalizumab study by year-end, after a €30M financing extending its cash runway into 2028.

Innate Pharma SA (Euronext Paris: IPH, Nasdaq: IPHA) announced a proposed private placement offering of about €22.5 million of ordinary shares. Net proceeds will fund continued development of IPH4502, preclinical ADC candidates, and working capital. Cash runway is until end-Q3 2026, or Q3 2027 after a $75m Sobi upfront payment, subject to conditions.

Swedish Orphan Biovitrum (Sobi) and Innate Pharma agreed on a partnership to start the TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma, supporting an accelerated approval filing for lacutamab in Sézary syndrome. Sobi will pay Innate $75m at closing, with up to $40m in milestones, up to $465m for development rights and further milestones, plus tiered double-digit royalties.

Innate Pharma’s Sponsored ADR (NASDAQ:IPHA) saw short interest rise 171.5% in May, reaching 245,729 shares as of May 15 versus 90,515 on April 30, according to the article. Short interest equals 0.4% of shares; days to cover is 1.0. The stock traded at $1.83 midday. Analysts cited mixed ratings and targets ($5.00 average).

Innate Pharma S.A. (IPH.PA) stock is up 8.94% today as traders anticipate its earnings release on March 26, 2026. Key focuses for the earnings call will be updates on Phase III Monalizumab and Phase II Lacutamab clinical programs, cash runway, and potential partnership milestones. Meyka AI gives IPH.PA a "HOLD" rating with an estimated 18.80% upside, but highlights risks such as high debt-to-equity and potential dilution.

Innate Pharma will host a conference call and webcast on Thursday, March 26, 2026, to discuss its financial results for the full year ending December 31, 2025. The event will feature key executives and will be accessible via webcast and telephone. A replay of the webcast will be available on the company's website for 90 days.

After losing some value lately, a hammer chart pattern has been formed for Innate Pharma (IPHA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Innate Pharma S.A.

Q1 sales rose 10.8% to $10.42 billion, exceeding estimates on strength in Dupixent and new pharma products. Operating income climbed 20.1% to $3.06 billion, driven by innovation and favorable launch dynamics. Don't face extreme market conditions unprepared.